Related Experiment Video

Updated: May 4, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.5K

5-Aza-2<-deoxycytidine induces hepatoma cell apoptosis via enhancing methionine adenosyltransferase 1A expression and

Wei-Jun Liu1, Jian-Guo Ren, Ting Li

  • 1Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital, Wuhan University, Wuhan, China E-mail : lqy@whu. edu.cn, spss2005@126.com.

Asian Pacific Journal of Cancer Prevention : APJCP
|January 1, 2014
PubMed

Insights

The demethylating drug 5-aza-2<-deoxycitidine (5-Aza-CdR) reactivates methionine adenosyltransferase 1A (MAT1A) in hepatocellular cancer cells. This epigenetic reprogramming inhibits cancer growth and induces apoptosis by increasing S-adenosylmethionine (SAMe) production.

Area of Science:

  • Hepatocellular Carcinoma (HCC) Research
  • Epigenetics and Cancer Biology
  • Pharmacology and Drug Discovery

Background:

  • Hepatocellular cancer (HCC) often exhibits resistance to conventional therapies due to epigenetic alterations.
  • Methionine adenosyltransferase 1A (MAT1A) inactivation, linked to promoter hypermethylation, is implicated in HCC progression.
  • Epigenetic modifying drugs are explored to reverse aberrant gene silencing in cancer.

Purpose of the Study:

  • To investigate the impact of the demethylating agent 5-aza-2<-deoxycitidine (5-Aza-CdR) on MAT1A gene expression, DNA methylation, and S-adenosylmethionine (SAMe) production in Huh7 HCC cells.
  • To evaluate the anti-tumor effects of 5-Aza-CdR, including its influence on cell growth, apoptosis, and related molecular markers.

Main Methods:

  • Treatment of Huh7 HCC cells with 5-aza-2<-deoxycitidine (5-Aza-CdR).
  • Assessment of MAT1A and MAT2A mRNA and protein expression levels.
  • Analysis of DNA methylation status at the MAT1A promoter.
  • Measurement of S-adenosylmethionine (SAMe) production.
  • Evaluation of cell proliferation, apoptosis markers (Bcl-2, Bax, caspase-3).

Main Results:

  • 5-Aza-CdR treatment significantly increased MAT1A mRNA and protein expression in Huh7 cells.
  • Demethylation of the MAT1A promoter was observed following 5-Aza-CdR treatment.
  • MAT2A expression decreased, while SAMe production was significantly induced by 5-Aza-CdR.
  • 5-Aza-CdR inhibited Huh7 cell growth and induced apoptosis via modulation of Bcl-2, Bax, and caspase-3.
  • No effect of 5-Aza-CdR on MAT2A methylation was detected.

Conclusions:

  • 5-Aza-CdR exerts anti-tumor effects in HCC cells by epigenetically upregulating MAT1A expression.
  • The observed therapeutic effects are associated with increased SAMe production and induction of apoptosis.
  • Targeting epigenetic repression offers a promising strategy for HCC treatment.

More Related Videos

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

7.3K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
915
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K